Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Drugs developed to target particular genetic changes may not be right for every person whose cancer shows those alterations or mutations.
Learn about promising clinical trial results and new treatment approaches for melanoma, a serious type of skin cancer.
Thanks to groundbreaking immunotherapy research, Jane Hart enjoys every day without laryngeal cancer.
Chase Griffith, 45, lives in Dallas with his wife and two sons. He has metastatic chromophobe renal cell carcinoma.
“I worry for my patients,” says a researcher at the Chicago CORE center. The pause also affects trials for cancer, COVID and mpox.
Tecentriq (atezolizumab) is the first drug approved approved for advanced alveolar soft part sarcoma, a rare cancer.
Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.
A personalized cancer vaccine plus Keytuda lowered the risk of melanoma coming back after surgery.
The new director of the National Cancer Institute says her prognosis is very favorable.
Patient advocate Melvin Mann was diagnosed with chronic myeloid leukemia in 1995. He has been in treatment and in remission since 1998.
The American Cancer Society awarded $4.2 million in patient navigation grants to 14 health care systems.
Today, more than half of patients diagnosed with advanced melanoma and treated with new therapies are alive five years after diagnosis.
Genomic testing is an important tool to guide treatment decisions among women with early-stage breast cancer.
Nearly 70% of the approximately 10 million cancer deaths that occur globally every year take place in low- and middle-income countries.
Phase I cancer clinical trials are more beneficial for participants than they used to be, says Naoko Takebe, MD, PhD.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.